Pureに変更を加えた場合、すぐここに表示されます。

研究成果 1998 2019

フィルター
評論記事
2019
1 引用 (Scopus)

First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the ‘real-world’ clinical setting

Park, K., Wan-Teck Lim, D., Okamoto, I. & Yang, J. C. H., 4 1 2019, : : Therapeutic Advances in Medical Oncology. 11

研究成果: ジャーナルへの寄稿評論記事

公開
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Mutation
Lung
Therapeutics
2018
2 引用 (Scopus)

Anticancer drug treatment for advanced lung cancer with interstitial lung disease

Otsubo, K., Okamoto, I., Hamada, N. & Nakanishi, Y., 7 1 2018, : : Respiratory Investigation. 56, 4, p. 307-311 5 p.

研究成果: ジャーナルへの寄稿評論記事

Interstitial Lung Diseases
Lung Neoplasms
Pharmaceutical Preparations
Drug Therapy
Therapeutics
2 引用 (Scopus)

Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non–small cell lung cancer

Iwama, E., Nakanishi, Y. & Okamoto, I., 3 4 2018, : : Expert Review of Anticancer Therapy. 18, 3, p. 267-276 10 p.

研究成果: ジャーナルへの寄稿評論記事

Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
2015

Clinical benefits associated with first line treatment using afatinib

Iwama, E. & Okamoto, I., 10 20 2015, : : Japanese Journal of Lung Cancer. 55, 6, p. 866-870 5 p.

研究成果: ジャーナルへの寄稿評論記事

Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Therapeutics
Mutation
Paronychia
6 引用 (Scopus)

Clinical development of nintedanib for advanced non-small-cell lung cancer

Takeda, M., Okamoto, I. & Nakagawa, K., 11 16 2015, : : Therapeutics and Clinical Risk Management. 11, p. 1701-1706 6 p.

研究成果: ジャーナルへの寄稿評論記事

docetaxel
Non-Small Cell Lung Carcinoma
cancer
Cells
Toxicity
2014
3 引用 (Scopus)

Current status and future perspectives of cooperative study groups for lung cancer in Japan

Kawano, Y., Okamoto, I., Fukuda, H., Ohe, Y., Nakamura, S., Nakagawa, K., Hotta, K., Kiura, K., Takiguchi, Y., Saka, H., Okamoto, H., Takayama, K., Semba, H., Kobayashi, K., Kenmotsu, H., Tsuboi, M., Yamamoto, N., Nukiwa, T. & Nakanishi, Y., 11 1 2014, : : Respiratory Investigation. 52, 6, p. 339-347 9 p.

研究成果: ジャーナルへの寄稿評論記事

Lung Neoplasms
Japan
Clinical Trials
Research Personnel
Therapeutics
30 引用 (Scopus)

Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer

Iwama, E., Okamoto, I., Harada, T., Takayama, K. & Nakanishi, Y., 3 5 2014, : : OncoTargets and Therapy. 7, p. 375-385 11 p.

研究成果: ジャーナルへの寄稿評論記事

Lung Neoplasms
Non-Small Cell Lung Carcinoma
anaplastic lymphoma kinase
United States Food and Drug Administration
Oncogenes
2013
15 引用 (Scopus)

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

Kaneda, H., Yoshida, T. & Okamoto, I., 5 29 2013, : : Cancer Management and Research. 5, 1, p. 91-101 11 p.

研究成果: ジャーナルへの寄稿評論記事

Non-Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Protein-Tyrosine Kinases
Mutation
erbB-1 Genes
2012
11 引用 (Scopus)
Non-Small Cell Lung Carcinoma
Therapeutics
Oncogenes
Protein-Tyrosine Kinases
MAP4

EGFR

Okamoto, K. & Okamoto, I., 12 1 2012, : : Respiration and Circulation. 60, 12, p. 1215-1220 6 p.

研究成果: ジャーナルへの寄稿評論記事

2010
20 引用 (Scopus)
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
Protein-Tyrosine Kinases
Mutation
Therapeutics
2009
21 引用 (Scopus)

S-1: A new oral fluoropyrimidine in the treatment of patients with advanced non-small-cell lung cancer

Okamoto, I. & Fukuoka, M., 1 1 2009, : : Clinical Lung Cancer. 10, 4, p. 290-294 5 p.

研究成果: ジャーナルへの寄稿評論記事

Non-Small Cell Lung Carcinoma
irinotecan
gemcitabine
Platinum Compounds
Tegafur
2007
21 引用 (Scopus)

Amrubicin for non-small-cell lung cancer and small-cell lung cancer

Kurata, T., Okamoto, I., Tamura, K. & Fukuoka, M., 10 1 2007, : : Investigational New Drugs. 25, 5, p. 499-504 6 p.

研究成果: ジャーナルへの寄稿評論記事

Small Cell Lung Carcinoma
Non-Small Cell Lung Carcinoma
Cisplatin
Clinical Trials
Topoisomerase II Inhibitors